<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03611491</url>
  </required_header>
  <id_info>
    <org_study_id>CPH-401-201324</org_study_id>
    <nct_id>NCT03611491</nct_id>
  </id_info>
  <brief_title>Post Market Study Evaluating Princess Filler Lidocaine for the Correction of Nasolabial Folds</brief_title>
  <acronym>FINO</acronym>
  <official_title>A Prospective, Open Label, Multicenter, Post Market Study Evaluating Princess® FILLER Lidocaine for the Correction of Nasolabial Folds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Croma-Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Croma-Pharma GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, eligible subjects with moderate to severe nasolabial folds will be treated
      with Princess® FILLER Lidocaine and will return for follow-up assessments 2, 4, 24 and 36
      weeks after the treatment. A Touch-up treatment may be done at Week 2, if deemed appropriate
      by the investigator
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 20, 2017</start_date>
  <completion_date type="Actual">November 19, 2018</completion_date>
  <primary_completion_date type="Actual">November 19, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The average change versus baseline in the NLF-SRS grade of nasolabial folds at Week 24 as evaluated by the investigator</measure>
    <time_frame>baseline, Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nasolabial fold severity (NLF-SRS) Weeks 4 and 36</measure>
    <time_frame>1 and 9 months post injection</time_frame>
    <description>The average change versus Baseline in the NLF-SRS grade at Week 4 and Week 36 after initial treatment as evaluated by the investigator</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Correction of Nasolabial Folds</condition>
  <arm_group>
    <arm_group_label>Princess® FILLER Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Princess FILLER Lidocaine injections up to 10 ml given to the patients at baseline time point</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Princess FILLER Lidocaine</intervention_name>
    <description>Princess FILLER Lidocaine injection up to 10 ml given to the patients at baseline time point. After 2 week a touch up is given in case to be consider necessary.</description>
    <arm_group_label>Princess® FILLER Lidocaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female 18 years of age or older

          2. Presence of two fully visible, approximately symmetrical nasolabial folds, with each
             of the folds scored 2-3 according to the 5-grade NLF-SRS as assessed by the
             investigator

          3. Healthy skin in the facial area and free of diseases that could interfere in cutaneous
             aging evaluation

          4. Willingness to abstain from any aesthetic or surgical procedures in the treatment area
             for the duration of the clinical investigation

          5. Written signed and dated informed consent

        Exclusion Criteria:

        Subjects meeting any of the following criteria should not be enrolled:

          1. Pregnancy, lactation, planned pregnancy or unwillingness to use contraception at any
             time during the study (for women of child-bearing potential only)

          2. History of mental disorders or emotional instability

          3. History of allergic reaction or hypersensitivity to hyaluronic acid, lidocaine, or any
             amide-based anaesthetic

          4. Presence of silicone implant or another non-absorbable substance (permanent fillers)
             in the nasolabial region

          5. Facial surgery or implantation of dermal fillers, absorbable and non-absorbable
             sutures, laser therapy, dermoabrasion, or botulinum toxin application in the
             nasolabial region within previous twelvemonths, or chemical peeling within previous
             three months, or planning to undergo such procedures in the treatment area during the
             study

          6. Presence of infectious, inflammatory, or proliferative lesions in the nasolabial
             region

          7. Cutaneous lesions in the treatment area

          8. Known human immune deficiency virus-positive individuals

          9. History of allergies against aesthetic filling products and recurrent herpes simplex

         10. Tendency to hypertrophic scars, keloid formation and/or pigmentation disorders

         11. History or presence of any autoimmune or connective tissue disease, or current
             treatment with immune therapy

         12. Diabetes mellitus or uncontrolled systemic diseases

         13. Use of anticoagulant, antiplatelet or thrombolytic medication from ten days pre- to
             three days post injection

         14. Any medical condition which, in the investigator's opinion, prohibits the inclusion in
             the study

         15. Current or previous (within 30 days of enrolment) treatment with another
             investigational drug and/or medical device or participation in another clinical study

         16. Previous enrolment in this clinical investigation

         17. Subjects whose participation in clinical trials is prohibited by the Austrian Medical
             Devices Act (e.g., persons with a legal custodian appointed due to mental disability,
             prisoners, soldiers and other members of the armed forces, civil servants)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MÄZ WIEN Medizinisch Ästhetisches Zentrum Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yuvell</name>
      <address>
        <city>Vienna</city>
        <zip>1010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>August 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>February 24, 2019</last_update_submitted>
  <last_update_submitted_qc>February 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

